Cargando…

Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer

Detalles Bibliográficos
Autores principales:	Abbosh, C, Swanton, C, Birkbak, N J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889023/ https://www.ncbi.nlm.nih.gov/pubmed/29351578 http://dx.doi.org/10.1093/annonc/mdy017

Ejemplares similares

Landscape of circulating tumour DNA in metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2020)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?
por: Polasik, Arkadius, et al.
Publicado: (2017)

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer
por: Chin, Yoon Ming, et al.
Publicado: (2022)

Therapy drives genomic evolution in metastatic cancer
por: Christensen, Ditte S., et al.
Publicado: (2023)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Circulating tumour-derived DNA in metastatic soft tissue sarcoma
por: Eastley, Nicholas C., et al.
Publicado: (2018)

Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients
por: Muendlein, Axel, et al.
Publicado: (2021)

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2022)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel
por: Kisistók, Judit, et al.
Publicado: (2023)

Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
por: Asghar, Uzma S., et al.
Publicado: (2022)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
por: Martínez-Sáez, Olga, et al.
Publicado: (2021)

Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer
por: Kirwan, C. C., et al.
Publicado: (2019)

Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells
por: Blain, Stacy W.
Publicado: (2018)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
por: Murtaza, Muhammed, et al.
Publicado: (2015)

Computational optimisation of targeted DNA sequencing for cancer detection
por: Martinez, Pierre, et al.
Publicado: (2013)

Genomic profile of advanced breast cancer in circulating tumour DNA
por: Kingston, Belinda, et al.
Publicado: (2021)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
por: Abu-Khalaf, Maysa M., et al.
Publicado: (2023)

Concerning the article by Louveau et al “Clinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor”
por: Robert, Caroline
Publicado: (2017)

Electromagnetic Medical Sensing
por: Abbosh, Amin
Publicado: (2019)

CDK4/6 inhibition: the late harvest cycle begins
por: Goel, Shom, et al.
Publicado: (2016)

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
por: Chabon, Jacob J., et al.
Publicado: (2016)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Modelling Circulating Tumour Cells for Personalised Survival Prediction in Metastatic Breast Cancer
por: Ascolani, Gianluca, et al.
Publicado: (2015)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
por: Prat, Aleix, et al.
Publicado: (2023)

The Role of CDK5 in Tumours and Tumour Microenvironments
por: Do, Phuong Anh, et al.
Publicado: (2020)

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study
por: Zivanovic Bujak, Andjelija, et al.
Publicado: (2020)

A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables
por: Endesfelder, David, et al.
Publicado: (2011)

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses
por: van Rees, Jan M., et al.
Publicado: (2023)

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma
por: Thieme, Elana, et al.
Publicado: (2023)

Gene Expression and DNA Methylation as Prognostic Markers in Metastatic Castration-Resistant Prostate Cancer: Analysis of Circulating Tumor Cells and Paired Plasma-Derived Exosomes
por: Hussein, Mohamed Ali, et al.
Publicado: (2023)

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
por: Gremel, G., et al.
Publicado: (2016)

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
por: Chabon, Jacob J., et al.
Publicado: (2016)

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance
por: Hu, Zhe-Yu, et al.
Publicado: (2018)

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
por: Chimonidou, Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mh0rrgt8b9gik99u92v7dgj992